GlassScriptPhysician profile
David T Vance
NPI 1205001799
$8,712.33
in general payments reported to CMS, 2019-2025
25 companies · $786 in 2025
The $786 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,245 · 2020: $725 · 2021: $1,212 · 2022: $757 · 2023: $757 · 2024: $3,231 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,128 · Travel and Lodging: $1,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,127.97 |
| Travel and Lodging | $1,646.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,629.87 | 2019-2025 | Aveir, Ensite, Assurity |
| Biosense Webster, INC. | $886.65 | 2019-2024 | Carto 3, Qdot Micro Catheter |
| Medtronic, INC. | $500.01 | 2022-2025 | Affera Mapping System, Aurora Ev-Icd Mri Surescan, Pulseselect |
| Boston Scientific Corporation | $478.25 | 2019-2025 | General - Therapies, Eluvia, Avvigo Guidance System |
| Janssen Pharmaceuticals, INC | $207.68 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $196.10 | 2019-2022 | |
| Atricure, INC. | $155.87 | 2025 | Synergy Ablation System, Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Daxor Corporation | $92.59 | 2024 | Bva-100 |
| Philips North America LLC | $89.83 | 2022-2025 | Labosys |
| Abiomed | $79.60 | 2019-2023 | Impella |
| Pfizer INC. | $72.92 | 2019-2021 | |
| Medtronic Vascular, INC. | $60.19 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.65 | 2019-2024 | Lifevest |
| Sumitomo Pharma America, INC. | $28.30 | 2025 | Gemtesa |
| Avinger INC. | $24.61 | 2023 | Pantheris |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23.01 | 2019 | |
| Terumo Medical Corporation | $21.09 | 2025 | R2p Misago, Glidesheath Slender, Metacross Otw |
| Otsuka America Pharmaceutical, INC. | $18.12 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.79 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.50 | 2019 | |
| Edwards Lifesciences Corporation | $12.74 | 2020 | |
| Acutus Medical, INC. | $12.52 | 2020 | |
| Amgen INC. | $12.25 | 2019 | |
| Cardinal Health 200 LLC | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.